Exa vs Tempus AI
A side-by-side look at scores, pricing and features — with RECATOOLS' ASEAN-aware verdict for each.
Exa
Web search and retrieval API built for AI agents and apps
Visit
|
|
|
|---|---|---|
| RECATOOLS Score | 7.7 / 10 | 8.2 / 10 |
| Capability | ||
| Value for money | ||
| Ease of use | ||
| ASEAN readiness | ||
| API quality | ||
| Pricing | Freemium | Enterprise |
| Free tier | 20,000 search requests per month on the free plan; startup and education grants of $1,000 in free API credits also available | No free tier; enterprise contracts only |
| Paid from | API search billed at $7 per 1,000 requests (as of March 2026 pricing update) | Custom enterprise contracts; multi-year data-licensing subscriptions (price not publicly disclosed) |
| Has API | ✓ | ✓ |
| Open source | ✗ | ✗ |
| Free to use | ✓ | ✗ |
| Users | — | ~50% of US oncologists; 4,500+ hospital integrations; 40M+ clinical records |
| Founded | 2021 | 2015 |
| Maker | — | Tempus AI, Inc. (independent, Nasdaq: TEM) |
| Verdict | Exa is a credible, fast-moving entrant in the agent-search space, with a clean API, MCP support and strong investor backing as of 2026. It competes directly with Parallel and Tavily on freshness and structured retrieval... |
Tempus AI is among the most data-rich precision oncology platforms in existence, with a self-reinforcing flywheel of clinical sequencing, molecular data, and real-world outcomes that no pure-software competitor can easil... |
| Full review → | Full review → |
← Back to AI Directory
Comparisons cover up to 4 tools. Scores are RECATOOLS editorial assessments; verify current pricing on each vendor's site.